• Profile
Close

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era

International Journal of Cancer Oct 17, 2019

Hellesnes R, Kvammen O, Myklebust TA, et al. - Researchers determined the risk of second cancer (SC) in testicular cancer survivors (TCS) treated in the cisplatin era, by analyzing full information on total treatment burden. Using the Cancer Registry of Norway, 5,625 1-year TCS diagnosed 1980-2009 were selected. Participants were observed over a median duration of 16.6 years. Overall 651 non-germ cell SCs were developed by 572 TCS. A raised SC risk was reported following surgery only, with site-specific elevated risks of thyroid cancer and melanoma. The risks for cancers of the small intestine, bladder, kidney and lung were increased 2.0-3.7-fold following chemotherapy (CT). Following ≥ 2 cycles of cisplatin-based CT, a 1.6-2.1-fold elevated risk of SC was observed. A link of radiotherapy (RT) with 1.5-4.4-fold raised risks for cancers of the stomach, small intestine, liver, pancreas, lung, kidney and bladder, was noted. Risks of haematological malignancies increased following combined CT and RT. Overall, an increased risk of developing SC was observed for TCS treated in the cisplatin era, this was especially noted after therapy with cisplatin-based CT and/or RT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay